Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ardelyx

4.82
+0.21504.67%
Post-market: 4.860.0445+0.92%19:55 EDT
Volume:5.06M
Turnover:23.98M
Market Cap:1.15B
PE:-28.94
High:4.83
Open:4.60
Low:4.55
Close:4.60
Loading ...

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

GlobeNewswire
·
17 Apr

Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Insider Monkey
·
16 Apr

April 2025's Top Penny Stocks To Watch

Simply Wall St.
·
16 Apr

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

GlobeNewswire
·
01 Apr

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

GlobeNewswire
·
13 Mar

High Growth Tech Stocks In The US With Promising Potential

Simply Wall St.
·
11 Mar

Vistra, Ardelyx, Zscaler, Lexicon, Arista: Trending by Analysts

TIPRANKS
·
08 Mar

Ardelyx Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Ardelyx Coverage Assumed by Ladenburg Thalmann at Buy

Dow Jones
·
07 Mar

Ardelyx price target lowered to $11 from $13.50 at Ladenburg

TIPRANKS
·
07 Mar

Ardelyx initiated with an Outperform at Scotiabank

TIPRANKS
·
07 Mar

BTIG Initiates Ardelyx at Buy With $14 Price Target

MT Newswires Live
·
04 Mar

BTIG initiates Ardelyx with a Buy, sees attractive entry point after pullback

TIPRANKS
·
04 Mar

Ardelyx initiated with a Buy at BTIG

TIPRANKS
·
04 Mar

Ardelyx Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
27 Feb

BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences

Reuters
·
27 Feb

Ardelyx Shares up 1.2% as China Approves Co's Kidney Disease Drug

THOMSON REUTERS
·
26 Feb

Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell

MT Newswires Live
·
26 Feb

BUZZ-Ardelyx rises as China approves kidney disease drug

Reuters
·
26 Feb

Stock Track | Ardelyx Soars 7.72% Pre-Market on China Approval of Tenapanor for Hyperphosphatemia

Stock Track
·
26 Feb